⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28936399 | 0.96 | — | — | |
| SCHEMBL18424387 | 0.96 | — | — | |
| Benzene SCHEMBL18631521 | 0.93 | — | — | |
| Ethane SCHEMBL1862515 | 0.93 | — | — | |
| SCHEMBL56295 | 0.79 | — | — | |
| Water SCHEMBL1896735 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL2731248 | 0.76 | — | — | |
| Water SCHEMBL26966454 | 0.76 | — | — | |
| SCHEMBL30773896 | 0.74 | — | — | |
| SCHEMBL2554291 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085069-A1 | PRODRUGS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-26 | — | — | US | claimed |
| EP-4697428-A1 | LITHIUM SECONDARY BATTERY | LG Energy Solution, Ltd. (KR) | 2026-02-18 | — | — | EP | claimed |
| EP-4307428-B1 | NOVEL ADDITIVE FOR NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG ENERGY SOLUTION LTD (KR) | 2026-01-28 | — | — | EP | claimed |
| US-20260022192-A1 | RECOMBINANT OLIGOSACCHARYLTRANSFERASES AND METHODS OF USE THEREOF | UNIV CORNELL (US) | 2026-01-22 | — | — | US | claimed |
| EP-3891220-B1 | FLUORO-THERMOPLASTIC ELASTOMER BLENDS | ARKEMA INC (US) | 2025-11-05 | — | — | EP | claimed |
| EP-4584268-A1 | PRODRUGS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | claimed |
| WO-2025137158-A1 | DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| US-20240213534-A1 | NOVEL ADDITIVE FOR NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG ENERGY SOLUTION, LTD. (KR) | 2024-06-27 | — | — | US | claimed |
| WO-2024052693-A1 | PRODRUGS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | claimed |
| EP-4307428-A1 | NOVEL ADDITIVE FOR NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG Energy Solution, Ltd. (KR) | 2024-01-17 | — | — | EP | claimed |
| WO-2023177074-A1 | NOVEL ADDITIVE FOR NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY COMPRISING SAME | 주식회사 엘지에너지솔루션 | 2023-09-21 | — | — | WO | claimed |
| EP-3436524-B1 | 3-D PRINTED FLUOROPOLYMER STRUCTURES | ARKEMA INC (US) | 2022-06-15 | — | — | EP | claimed |
| CN-114426548-A | Preparation method and system of dicyclopentadiene dioxide | 中国石油化工股份有限公司 | 2022-05-03 | — | — | CN | claimed |
| CN-110835336-A | Oxygen-containing heterocyclic substituted azole compound and application thereof | 中国药科大学 | 2020-02-25 | — | — | CN | claimed |
| WO-2007148344-A2 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | MATRIX LABORATORIES LIMITED (IN) | 2007-12-27 | — | — | WO | claimed |
| EP-1140203-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000035488-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| EP-0939757-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | Dupont Pharmaceuticals Company (US) | 1999-09-08 | — | — | EP | claimed |
| WO-1997023480-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-07-03 | — | — | WO | claimed |
| WO-2026100156-A1 | OPTICAL COMMUNICATION SYSTEM | 慶應義塾 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026100646-A1 | OPTICAL COMMUNICATION SYSTEM | 慶應義塾 | 2026-05-15 | — | — | WO | disclosed |
| US-20260091051-A1 | USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF PAIN, AND CORRESPONDING COMPOSITIONS | NUVAMID SA (CH) | 2026-04-02 | — | — | US | disclosed |
| US-20260085069-A1 | PRODRUGS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| US-20260071013-A1 | COMPOSITION CONTAINING FLUORINE-CONTAINING POLYMER, METHOD FOR PRODUCING FLUORINE-CONTAINING POLYMER, AND ULTRAVIOLET LIGHT-EMITTING ELEMENT LENS CONTAINING FLUORINE-CONTAINING POLYMER | DAIKIN INDUSTRIES, LTD. (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-4697428-A1 | LITHIUM SECONDARY BATTERY | LG Energy Solution, Ltd. (KR) | 2026-02-18 | — | — | EP | disclosed |
| EP-4307428-B1 | NOVEL ADDITIVE FOR NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG ENERGY SOLUTION LTD (KR) | 2026-01-28 | — | — | EP | disclosed |
| US-20260022192-A1 | RECOMBINANT OLIGOSACCHARYLTRANSFERASES AND METHODS OF USE THEREOF | UNIV CORNELL (US) | 2026-01-22 | — | — | US | disclosed |
| US-12392957-B2 | Integrally molded multi-optical transmission sheet, integrally molded multi-optical transmission sheet connector and method for manufacturing the same | KOIKE YASUHIRO (JP) | 2025-08-19 | — | — | US | disclosed |
| US-20250257072-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | SHIONOGI & CO., LTD. (JP) | 2025-08-14 | — | — | US | disclosed |
| EP-4584268-A1 | PRODRUGS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| EP-3744721-B1 | CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT | SHIONOGI & CO (JP) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025137158-A1 | DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-120035635-A | Preparation of large particle size fluoropolymer latex | 阿科玛股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-119968443-A | Preparation of large particle size functionalized fluoropolymer latex | 阿科玛股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-4543872-A1 | MULTI-PHOTOPROTECTIVE COMPOUNDS AND USES THEREOF | SKINOSIVE (FR) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-115093408-B | Benzylamine-containing 5, 6-heteroaromatic compounds useful against mycobacterial infections | 盐野义制药株式会社 | 2025-03-11 | — | — | CN | disclosed |
| WO-2025021193-A1 | STEROID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| WO-2025020191-A1 | STEROID COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| WO-2025021195-A1 | STEROID COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| WO-2025020190-A1 | STEROID COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-112313238-B | Tetrahydropyranoxazine derivatives with selective BACE1 inhibiting activity | 盐野义制药株式会社 | 2025-01-17 | — | — | CN | disclosed |
| WO-2024241998-A1 | COMPOSITION CONTAINING FLUORINE-CONTAINING POLYMER, METHOD FOR PRODUCING FLUORINE-CONTAINING POLYMER, AND ULTRAVIOLET LIGHT-EMITTING ELEMENT LENS CONTAINING FLUORINE-CONTAINING POLYMER | ダイキン工業株式会社 | 2024-11-28 | — | — | WO | disclosed |
| EP-4458348-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | Shionogi & Co., Ltd (JP) | 2024-11-06 | — | — | EP | disclosed |
| US-20240327424-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO (JP) | 2024-10-03 | — | — | US | disclosed |
| CN-118678949-A | Novel B0AT1 inhibitors | 田边三菱制药株式会社 | 2024-09-20 | — | — | CN | disclosed |
| EP-4424314-A2 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE AND PRODRUG THEREOF | Shionogi & Co., Ltd (JP) | 2024-09-04 | — | — | EP | disclosed |
| EP-3606714-B1 | SHRINK WRAP LABEL COATING TO FACILITATE RECYCLING | SUN CHEMICAL CORP (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20240213534-A1 | NOVEL ADDITIVE FOR NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG ENERGY SOLUTION, LTD. (KR) | 2024-06-27 | — | — | US | disclosed |
| EP-3957627-B1 | 6-MEMBERED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SHIONOGI & CO (JP) | 2024-06-19 | — | — | EP | disclosed |
| CN-118201911-A | Compounds and their use as GPR183 inhibitors | 南京艾美斐生物医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240195503-A1 | OPTICAL TRANSMISSION SYSTEM, OPTICAL TRANSMISSION PATH, AND PHOTOELECTRIC COMPOSITE CABLE | YASUHIRO KOIKE (JP) | 2024-06-13 | — | — | US | disclosed |
| US-20240122957-A1 | USE OF NICOTINAMIDE MONONUCLEOTIDE (NMN) FOR THE PREVENTION AND/OR TREATMENT OF RHEUMATOID ARTHRITIS, AND CORRESPONDING COMPOSITIONS | NUVAMID SA (CH) | 2024-04-18 | — | — | US | disclosed |
| EP-4084799-B1 | USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF JOINT PAIN INDUCED BY PHYSICAL ACTIVITY, AND CORRESPONDING COMPOSITIONS | NUVAMID SA (CH) | 2024-04-17 | — | — | EP | disclosed |
| CN-117838878-A | Antibody-STING agonist conjugates and their use in immunotherapy | 免疫传感器治疗股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117794918-A | Substituted tetrahydrofuran analogues as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-111527099-B | Selective inhibitors of protein arginine methyltransferase 5 (PRMT 5) | 普莱鲁德疗法有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2024052693-A1 | PRODRUGS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| US-11925689-B2 | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same | SERINA THERAPEUTICS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20240053529-A1 | INTEGRALLY MOLDED MULTI-OPTICAL TRANSMISSION SHEET, INTEGRALLY MOLDED MULTI-OPTICAL TRANSMISSION SHEET CONNECTOR AND METHOD FOR MANUFACTURING THE SAME | KOIKE YASUHIRO (JP) | 2024-02-15 | — | — | US | disclosed |
| EP-4322426-A1 | OPTICAL TRANSMISSION SYSTEM, OPTICAL TRANSMISSION PATH, AND OPTICAL-ELECTRICAL COMPOSITE CABLE | Koike, Yasuhiro (JP) | 2024-02-14 | — | — | EP | disclosed |
| US-11897899-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2024-02-13 | — | — | US | disclosed |
| WO-2024024050-A1 | OPTICAL TRANSMISSION LINE, OPTICAL TRANSMISSION SYSTEM, AND OPTICAL TRANSMISSION LINE CONNECTION METHOD | 小池 康博 | 2024-02-01 | — | — | WO | disclosed |
| CN-117460736-A | Nucleoside derivatives having multi-target phosphorylase inhibitory activity and pharmaceutical compositions for preventing and treating cancer comprising the same | 未来制药有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-4307428-A1 | NOVEL ADDITIVE FOR NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG Energy Solution, Ltd. (KR) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023247598-A1 | MULTI-PHOTOPROTECTIVE COMPOUNDS AND USES THEREOF | SKINOSIVE (FR) | 2023-12-28 | — | — | WO | disclosed |
| CN-114786729-B | Antibody-STING agonist conjugates and their use in immunotherapy | 免疫传感器治疗股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230400623-A1 | INTEGRALLY MOLDED MULTI-OPTICAL TRANSMISSION SHEET, INTEGRALLY MOLDED MULTI-OPTICAL TRANSMISSION SHEET CONNECTOR AND METHOD FOR MANUFACTURING THE SAME | KOIKE YASUHIRO (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230400624-A1 | INTEGRALLY MOLDED MULTI-OPTICAL TRANSMISSION SHEET, INTEGRALLY MOLDED MULTI-OPTICAL TRANSMISSION SHEET CONNECTOR AND METHOD FOR MANUFACTURING THE SAME | KOIKE YASUHIRO (JP) | 2023-12-14 | — | — | US | disclosed |
| US-11828977-B2 | Integrally molded multi-optical transmission sheet, integrally molded multi-optical transmission sheet connector and method for manufacturing the same | KOIKE YASUHIRO (JP) | 2023-11-28 | — | — | US | disclosed |
| CN-117062804-A | 1, 3-substituted cyclobutyl derivatives and their use | 诺华股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| WO-2023177074-A1 | NOVEL ADDITIVE FOR NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY COMPRISING SAME | 주식회사 엘지에너지솔루션 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023177078-A1 | LITHIUM SECONDARY BATTERY | 주식회사 엘지에너지솔루션 | 2023-09-21 | — | — | WO | disclosed |
| US-20230287004-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| EP-3495363-B1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT | SHIONOGI & CO (JP) | 2023-08-23 | — | — | EP | disclosed |
| US-11730752-B2 | Use of NMN for the prevention and/or treatment of joint pain induced by physical activity, and corresponding compositions | NUVAMID SA (CH) | 2023-08-22 | — | — | US | disclosed |
| WO-2023147776-A1 | SYSTEMS AND METHODS FOR ENHANCED IMMUNOTHERAPIES | HANGZHOU QIHAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-08-10 | — | — | WO | disclosed |
| CN-114805375-B | N-phenylalkoxy dibenzoazepine compound, preparation method and medical application thereof | 徐州医科大学 | 2023-07-25 | — | — | CN | disclosed |
| US-20230210746-A1 | ANTI-AGING COSMETIC COMPOSITIONS COMPRISING NMN | NUVAMID SA (CH) | 2023-07-06 | — | — | US | disclosed |
| US-11685740-B2 | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2023-06-27 | — | — | US | disclosed |
| US-20230172959-A1 | USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF A BACK PAIN AND CORRESPONDING COMPOSITIONS | NUVAMID SA (CH) | 2023-06-08 | — | — | US | disclosed |
| EP-4185586-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2023-05-31 | — | — | EP | disclosed |
| US-20230149435-A1 | USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF MUSCLE, LIGAMENT OR TENDON PAIN INDUCED BY PHYSICAL ACTIVITY AND CORRESPONDING COMPOSITIONS | NUVAMID SA (CH) | 2023-05-18 | — | — | US | disclosed |
| US-20230136569-A1 | USE OF NMN TO REDUCE IMMUNODEPRESSION AND IMMUNOSENESCENCE | NUVAMID SA (CH) | 2023-05-04 | — | — | US | disclosed |
| US-11629154-B2 | Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2023-04-18 | — | — | US | disclosed |
| EP-4153323-A1 | ANTI-AGING COSMETIC COMPOSITIONS COMPRISING NMN | Nuvamid SA (CH) | 2023-03-29 | — | — | EP | disclosed |
| US-20230060438-A1 | USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF JOINT PAIN INDUCED BY PHYSICAL ACTIVITY, AND CORRESPONDING COMPOSITIONS | NUVAMID SA (CH) | 2023-03-02 | — | — | US | disclosed |
| EP-3784674-B1 | TETRAHYDROPYRANOOXAZINE DERIVATIVES HAVING SELECTIVE BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2023-02-22 | — | — | EP | disclosed |
| US-11578084-B2 | Condensed ring compounds having dopamine D3 receptor antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2023-02-14 | — | — | US | disclosed |
| US-20230002368-A1 | USE OF COMPOUNDS FOR THE PREVENTION AND/OR TREATMENT OF ANKYLOSING SPONDYLITIS, AND CORRESPONDING COMPOSITIONS | NUVAMID SA (CH) | 2023-01-05 | — | — | US | disclosed |
| EP-3290424-B1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | SHIONOGI & CO (JP) | 2023-01-04 | — | — | EP | disclosed |
| CN-115443066-A | Coated agricultural products and corresponding method | 阿比尔技术公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20220340566-A1 | BENZYL AMINE-CONTAINING 5,6-HETEROAROMATIC COMPOUNDS USEFUL AGAINST MYCOBACTERIAL INFECTION | SHIONOGI & CO., LTD. (JP) | 2022-10-27 | — | — | US | disclosed |
| WO-2022215366-A1 | OPTICAL TRANSMISSION SYSTEM, OPTICAL TRANSMISSION PATH, AND OPTICAL-ELECTRICAL COMPOSITE CABLE | 小池 康博 | 2022-10-13 | — | — | WO | disclosed |
| US-20220323477-A1 | USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF PAIN, AND CORRESPONDING COMPOSITIONS | NUVAMID SA (CH) | 2022-10-13 | — | — | US | disclosed |
| EP-4065129-A1 | USE OF COMPOUNDS FOR THE PREVENTION AND/OR TREATMENT OF ANKYLOSING SPONDYLITIS, AND CORRESPONDING COMPOSITIONS | Nuvamid SA (CH) | 2022-10-05 | — | — | EP | disclosed |
| CN-110835336-B | Oxygen-containing heterocyclic substituted azole compound and application thereof | 中国药科大学 | 2022-10-04 | — | — | CN | disclosed |
| CN-115093408-A | Benzylamine-containing 5, 6-heteroaromatic compounds useful against mycobacterial infections | 盐野义制药株式会社 | 2022-09-23 | — | — | CN | disclosed |
| US-11447484-B2 | Cyclic compound having dopamine D3 receptor antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2022-09-20 | — | — | US | disclosed |
| CN-115043879-A | Dihydroartemisinin derivative and preparation method thereof | 上海喀露蓝科技有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220281890-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | SHIONOGI & CO., LTD. (JP) | 2022-09-08 | — | — | US | disclosed |
| EP-3412663-B1 | NITROGEN-CONTAINING HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2022-09-07 | — | — | EP | disclosed |
| CN-108690045-B | Diarylethene compounds and uses thereof | 首诺加拿大公司 | 2022-08-30 | — | — | CN | disclosed |
| EP-4042507-A1 | COMPOSITION | Mexichem Fluor S.A. de C.V. (MX) | 2022-08-17 | — | — | EP | disclosed |
| US-20220251113-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2022-08-11 | — | — | US | disclosed |
| US-20220235047-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE | SHIONOGI & CO., LTD. (JP) | 2022-07-28 | — | — | US | disclosed |
| US-20220193243-A1 | MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME | SERINA THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| CN-114641569-A | Composition for translation and method for producing peptide | 中外制药株式会社 | 2022-06-17 | — | — | CN | disclosed |
| WO-2022119899-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN | SHIONOGI & CO., LTD. (JP) | 2022-06-09 | — | — | WO | disclosed |
| US-11345716-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2022-05-31 | — | — | US | disclosed |
| EP-3990429-A1 | TERTIARY AMINE DERIVATIVES AND THEIR USES FOR TREATING A VIRAL INFECTION | ENYO Pharma (FR) | 2022-05-04 | — | — | EP | disclosed |
| CN-114426548-A | Preparation method and system of dicyclopentadiene dioxide | 中国石油化工股份有限公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-114426548-A | Preparation method and system of dicyclopentadiene dioxide | 中国石油化工股份有限公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-114426547-A | Method for producing dicyclopentadiene dioxide by using molybdenum-based homogeneous catalyst and obtained dicyclopentadiene dioxide | 中国石油化工股份有限公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-114401965-A | Benzylamine-containing 5, 6-heteroaromatic compounds useful against mycobacterial infections | 盐野义制药株式会社 | 2022-04-26 | — | — | CN | disclosed |
| US-11306106-B2 | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof | SHIONOGI & CO., LTD. (JP) | 2022-04-19 | — | — | US | disclosed |
| CN-109415386-B | Boronic acid derivatives and their therapeutic use | QPEX生物制药有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-110041316-B | TAM family kinase/CSF 1R kinase inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3976031-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE | Shionogi & Co., Ltd (JP) | 2022-04-06 | — | — | EP | disclosed |
| CN-113544222-A | Electron beam-curable printing ink composition and electron beam-curable overprint varnish composition | 阪田油墨股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-3810576-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | Intervet International B.V. (NL) | 2021-04-28 | — | — | EP | disclosed |
| EP-3810571-A1 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | Intervet International B.V. (NL) | 2021-04-28 | — | — | EP | disclosed |
| CN-107365319-B | Modulation of chemosensory receptors and ligands associated therewith | 弗门尼舍公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-110835336-A | Oxygen-containing heterocyclic substituted azole compound and application thereof | 中国药科大学 | 2020-02-25 | — | — | CN | disclosed |
| WO-2020002238-A1 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | INTERVET INTERNATIONAL B.V. (NL) | 2020-01-02 | — | — | WO | disclosed |
| WO-2020002234-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | INTERVET INTERNATIONAL B.V. (NL) | 2020-01-02 | — | — | WO | disclosed |
| EP-3558939-A1 | COMPOUNDS USEFUL FOR TREATING A MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI INFECTION | Intervet International B.V. (NL) | 2019-10-30 | — | — | EP | disclosed |
| CN-106795118-B | Heterocyclic compound and their purposes as relevant orphan receptor (ROR) the GAMMA-T inhibitor of retinoids | 武田药品工业株式会社 | 2019-10-08 | — | — | CN | disclosed |
| CN-104822702-B | α-MSH and γ-MSH analog | TXP制药股份有限公司 | 2019-07-30 | — | — | CN | disclosed |
| CN-106008488-B | Cyanoindole analog derivative and its preparation method and application | 广东东阳光药业有限公司 | 2018-10-30 | — | — | CN | disclosed |
| US-10093629-B2 | Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-09 | — | — | US | disclosed |
| US-10087476-B2 | Process for hydrolyzing a pretreated feedstock and recovering lignin | IOGEN CORPORATION (CA) | 2018-10-02 | — | — | US | disclosed |
| EP-2272866-B1 | THERAPEUTICALLY ACTIVE ALPHA-MSH ANALOGUES | ABBVIE INC (US) | 2018-09-19 | — | — | EP | disclosed |
| WO-2018115421-A1 | COMPOUNDS USEFUL FOR TREATING A MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI INFECTION | INTERVET INTERNATIONAL B.V. (NL) | 2018-06-28 | — | — | WO | disclosed |
| US-9951116-B2 | Alpha- and gamma-MSH analogues | TXP PHARMA GMBH (CH) | 2018-04-24 | — | — | US | disclosed |
| US-20170174738-A1 | ALPHA- AND GAMMA-MSH ANALOGUES | TXP PHARMA GMBH (CH) | 2017-06-22 | — | — | US | disclosed |
| CN-106795118-A | Heterocyclic compound to they as related orphan receptor (ROR) the GAMMA T inhibitor of retinoids purposes | 武田药品工业株式会社 | 2017-05-31 | — | — | CN | disclosed |
| US-20170144973-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | Takenda Pharmaceutical Company Limited (JP) | 2017-05-25 | — | — | US | disclosed |
| US-9650343-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-16 | — | — | US | disclosed |
| EP-3164388-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2017-05-10 | — | — | EP | disclosed |
| US-9630924-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-25 | — | — | US | disclosed |
| US-9573903-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| US-9486495-B2 | Alpha-and gamma-MSH analogues | TXP PHARMA GMBH (CH) | 2016-11-08 | — | — | US | disclosed |
| CN-106008488-A | Cyan indoles derivative and preparation method and use thereof | 广东东阳光药业有限公司 | 2016-10-12 | — | — | CN | disclosed |
| US-20160273011-A1 | PROCESS FOR HYDROLYZING A PRETREATED FEEDSTOCK AND RECOVERING LIGNIN | IOGEN CORPORATION (CA) | 2016-09-22 | — | — | US | disclosed |
| US-20160176873-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160176822-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160176872-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| US-9365520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20160074469-A1 | ALPHA-AND GAMMA-MSH ANALOGUES | TXP PHARMA GMBH (CH) | 2016-03-17 | — | — | US | disclosed |
| US-9287052-B2 | Additives for dye-sensitized solar cells | MERCK PATENT GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| WO-2016002968-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | WO | disclosed |
| US-20160002169-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | US | disclosed |
| US-9227995-B2 | Peptides | Jacobsen, Øyvind (NO) | 2016-01-05 | — | — | US | disclosed |
| US-20150376254-A1 | GAMMA-MSH ANALOGUES | TXP PHARMA GMBH (CH) | 2015-12-31 | — | — | US | disclosed |
| US-9217023-B2 | Alpha- and gamma-MSH analogues | TXP PHARMA GMBH (CH) | 2015-12-22 | — | — | US | disclosed |
| EP-2944650-A1 | Alpha- and gamma- MSH analogues | TXP Pharma GmbH (CH) | 2015-11-18 | — | — | EP | disclosed |
| WO-2015162483-A1 | ALPHA- AND GAMMA-MSH ANALOGUES | TXP PHARMA GMBH (CH) | 2015-10-29 | — | — | WO | disclosed |
| CN-103497237-B | The alpha-MSH analogue of therapeutic activity | ABBVIE INC. (US) | 2015-10-28 | — | — | CN | disclosed |
| US-20150297672-A1 | Alpha- and gamma-MSH analogues | TXP PHARMA GMBH (CH) | 2015-10-22 | — | — | US | disclosed |
| CN-104822702-A | Alpha- and gamma-msh analogues | TXP PHARMA GMBH | 2015-08-05 | — | — | CN | disclosed |
| WO-2015081439-A1 | PROCESS FOR HYDROLYZING A PRETREATED FEEDSTOCK AND RECOVERING LIGNIN | IOGEN CORPORATION (CA) | 2015-06-11 | — | — | WO | disclosed |
| CN-104583185-A | Method for producing biaryl compound | API CORP | 2015-04-29 | — | — | CN | disclosed |
| EP-2722340-B1 | Alpha- and gamma-MSH analogues | TXP PHARMA GMBH (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-8859574-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2014-10-14 | — | — | US | disclosed |
| US-20140155328-A1 | ALPHA-AND GAMMA-MSH ANALOGUES | TXP PHARMA GMBH (CH) | 2014-06-05 | — | — | US | disclosed |
| CN-102112467-B | Pyrimidine derivative as kinase inhibitors | IRM LLC | 2014-04-30 | — | — | CN | disclosed |
| EP-2722340-A1 | Alpha- and gamma-MSH analogues | TXP Pharma GmbH (CH) | 2014-04-23 | — | — | EP | disclosed |
| US-8703702-B2 | Therapeutically active α-MSH analogues | ABBVIE INC. (US) | 2014-04-22 | — | — | US | disclosed |
| WO-2014057687-A1 | ANTIBODY-DRUG CONJUGATE | 第一三共株式会社 (JP) | 2014-04-17 | — | — | WO | disclosed |
| EP-2706993-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEUROPILIN INHIBITORS, AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF ANGIOGENIC DISORDERS AND CANCERS | Tragex Pharma (FR) | 2014-03-19 | — | — | EP | disclosed |
| CN-101273059-B | Therapeutically active alpha-MSH analogs | ABBVIE INC | 2014-02-19 | — | — | CN | disclosed |
| US-20130310361-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2013-11-21 | — | — | US | disclosed |
| US-20130292601-A1 | Additives for Dye-Sensitized Solar Cells | MERCK PATENT GMBH (DE) | 2013-11-07 | — | — | US | disclosed |
| US-8563508-B2 | Method for preventing or reducing acute renal failure by administration of therapeutically active α-MSH analogues | ABBVIE INC. (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2649625-A1 | ADDITIVES FOR DYE-SENSITIZED SOLAR CELLS | Merck Patent GmbH (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-20130252891-A1 | Therapeutically Active Alpha-MSH Analogues | ABBVIE INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8519129-B2 | Pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-08-27 | — | — | US | disclosed |
| US-20130217628-A1 | Therapeutically Active Alpha-MSH Analogues | ABBVIE INC. (US) | 2013-08-22 | — | — | US | disclosed |
| WO-2013118855-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | 塩野義製薬株式会社 (JP) | 2013-08-15 | — | — | WO | disclosed |
| US-8466104-B2 | Therapeutically active alpha MSH analogues | ABBVIE INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8440681-B2 | 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-14 | — | — | US | disclosed |
| EP-1919947-B1 | THERAPEUTICALLY ACTIVE ALPHA-MSH ANALOGUES | ABBVIE INC (US) | 2013-02-27 | — | — | EP | disclosed |
| CN-101085754-B | Fluorosulfates of hexafluoroisobutylene and its higher homologs and their derivatives | DU PONT | 2013-01-23 | — | — | CN | disclosed |
| WO-2012156289-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEUROPILIN INHIBITORS, AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF ANGIOGENIC DISORDERS AND CANCERS | TRAGEX PHARMA (FR) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012076093-A1 | ADDITIVES FOR DYE-SENSITIZED SOLAR CELLS | MERCK PATENT GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
| US-20110263479-A1 | Peptides | UNIVERSITETET I OSLO (NO) | 2011-10-27 | — | — | US | disclosed |
| EP-1432420-B1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARM INC (US) | 2011-07-13 | — | — | EP | disclosed |
| CN-102112467-A | Compounds and compositions as kinase inhibitors | IRM LLC | 2011-06-29 | — | — | CN | disclosed |
| CN-1749252-B | Compounds useful to treat retroviral infections | PHARMACIA & UPJOHN CO LLC (US) | 2011-06-08 | — | — | CN | disclosed |
| US-20110124858-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PEST CONTROL AGENT | NIPPON SODA CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110112063-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| EP-2318392-A2 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-05-11 | — | — | EP | disclosed |
| CN-1223271-B | Copolymers of Maleic anhydrdide or acid and fluorinated olefins, product comprising the copolymer | DU PONT | 2011-03-02 | — | — | CN | disclosed |
| EP-2272866-A2 | Therapeutically active alpha-MSH analogues | Action Pharma A/S (DK) | 2011-01-12 | — | — | EP | disclosed |
| US-20100298295-A1 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-25 | — | — | US | disclosed |
| US-20100216840-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2010-08-26 | — | — | US | disclosed |
| EP-1666044-B1 | Male contraceptive formulation comprising norethisterone | BAYER SCHERING PHARMA AG (DE) | 2010-07-21 | — | — | EP | disclosed |
| EP-2190826-A2 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-06-02 | — | — | EP | disclosed |
| WO-2010002655-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-01-07 | — | — | WO | disclosed |
| US-20090069242-A1 | THERAPEUTICALLY ACTIVE ALPHA MSH ANALOGUES | ACTION PHARMA A/S (DK) | 2009-03-12 | — | — | US | disclosed |
| WO-2009032668-A2 | 2 -BIPHENYLAMINO-4 -AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | WO | disclosed |
| CN-101313251-A | Apparatus for recycling alkane immersion liquids and methods of employment | DU PONT (US) | 2008-11-26 | — | — | CN | disclosed |
| EP-1919947-A1 | THERAPEUTICALLY ACTIVE ALPHA-MSH ANALOGUES | Action Pharma A/S (DK) | 2008-05-14 | — | — | EP | disclosed |
| US-20080070948-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080009520-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2008-01-10 | — | — | US | disclosed |
| WO-2007148344-A2 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | MATRIX LABORATORIES LIMITED (IN) | 2007-12-27 | — | — | WO | disclosed |
| CN-101092378-A | Fluorosulfates of hexafluoroisobutylene and its higher homologs and their derivatives | DU PONT (US) | 2007-12-26 | — | — | CN | disclosed |
| CN-101085753-A | Fluorosulfates of hexafluoroisobutylene and its higher homologs and their derivatives | DU PONT (US) | 2007-12-12 | — | — | CN | disclosed |
| CN-101085754-A | Fluorosulfates of hexafluoroisobutylene and its higher homologs and their derivatives | DU PONT (US) | 2007-12-12 | — | — | CN | disclosed |
| CN-101085752-A | Fluorosulfates of hexafluoroisobutylene and its higher homologs and their derivatives | DU PONT (US) | 2007-12-12 | — | — | CN | disclosed |
| US-7300928-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7291611-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7273857-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-25 | — | — | US | disclosed |
| CN-100334074-C | Fluorosulfates of hexafluoroisobutylene and its higher homologs and derivatives thereof | PONT AG DU (US) | 2007-08-29 | — | — | CN | disclosed |
| US-20070196360-A1 | SUCCINIMIDE AND MALEIMIDE DERIVATIVES AND THEIR USE AS TOPOISOMERASE II CATALYTIC INHIBITORS | TOPOTARGET A/S | 2007-08-23 | — | — | US | disclosed |
| CN-1329378-C | Compounds for the treatment of retroviral infections | PHARMACIA & UPJOHN CO LLC (US) | 2007-08-01 | — | — | CN | disclosed |
| CN-1981242-A | UV-transparent alkanes and methods of using them in vacuum and deep UV applications | DU PONT (US) | 2007-06-13 | — | — | CN | disclosed |
| EP-1267885-B1 | MALE CONTRACEPTIVE FORMULATION COMPRISING NORETHISTERONE AND TESTOSTERONE UNDECANOATE | SCHERING AG (DE) | 2007-03-07 | — | — | EP | disclosed |
| WO-2007022774-A1 | THERAPEUTICALLY ACTIVE α-MSH ANALOGUES | ACTION PHARMA A/S (DK) | 2007-03-01 | — | — | WO | disclosed |
| EP-1748993-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-02-07 | — | — | EP | disclosed |
| US-20060258707-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-11-16 | — | — | US | disclosed |
| US-20060205785-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-09-14 | — | — | US | disclosed |
| US-20060199799-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-09-07 | — | — | US | disclosed |
| CN-1829736-A | severe acute respiratory syndrome coronavirus | CHIRON CORP (US) | 2006-09-06 | — | — | CN | disclosed |
| US-7087593-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060142257-A1 | Male contraceptive formulation comprising norethisterone | NIESCHLAG EBERHARD | 2006-06-29 | — | — | US | disclosed |
| EP-1666044-A1 | Male contraceptive formulation comprising norethisterone | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-07 | — | — | EP | disclosed |
| EP-1341743-B1 | ORGANIC REACTIONS WITH CO GENERATING MATERIALS | BIOTAGE AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| US-7026282-B1 | Peptide antagonists of the human urokinase receptor and method for selecting them | Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning) (DK) | 2006-04-11 | — | — | US | disclosed |
| US-7025979-B2 | Male contraceptive formulation comprising norethisterone | SCHERING AG (DE) | 2006-04-11 | — | — | US | disclosed |
| CN-1749252-A | Compounds useful to treat retroviral infections | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-22 | — | — | CN | disclosed |
| EP-1373494-B1 | SUCCINIMIDE AND MALEIMIDE DERIVATIVES AND THEIR USE AS TOPOISOMERASE II CATALYTIC INHIBITORS | TOPOTARGET AS (DK) | 2006-03-01 | — | — | EP | disclosed |
| US-20060025402-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-02-02 | — | — | US | disclosed |
| EP-1618093-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2005116000-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2005-12-08 | — | — | WO | disclosed |
| EP-1432420-A4 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6958243-B2 | Performing a one-pot organic reaction, which includes carbon monoxide (CO) as reactant and does not use of an external gas source, by contacting a non-catalyzing CO releasing compound such as a metal carbonyl with an energy source | BIOTAGE AB (SE) | 2005-10-25 | — | — | US | disclosed |
| US-20050221389-A1 | Organic reactions with CO generating materials | BIOTAGE AB (SE) | 2005-10-06 | — | — | US | disclosed |
| US-6951849-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2005-10-04 | — | — | US | disclosed |
| CN-1665779-A | Fluorosulfates of hexafluoroisobutylene and its higher homologs and derivatives thereof | DU PONT (US) | 2005-09-07 | — | — | CN | disclosed |
| WO-2004094388-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-11-04 | — | — | WO | disclosed |
| CN-1539825-A | Compounds for the treatment of retroviral infections | �������Ŷ���Լ��������˾ | 2004-10-27 | — | — | CN | disclosed |
| WO-2004089942-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-1432420-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | Acadia Pharmaceuticals Inc. (US) | 2004-06-30 | — | — | EP | disclosed |
| CN-1154642-C | Compounds for the treatment of retroviral infections | �������Ŷ���Լ��������˾ | 2004-06-23 | — | — | CN | disclosed |
| US-20040067931-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. | 2004-04-08 | — | — | US | disclosed |
| EP-1373494-A2 | SUCCINIMIDE AND MALEIMIDE DERIVATIVES AND THEIR USE AS TOPOISOMERASE II CATALYTIC INHIBITORS | Topo Target A/S (DK) | 2004-01-02 | — | — | EP | disclosed |
| US-20030100545-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003028650-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| US-20030032625-A1 | Succinimide and maleimide derivatives and their use as topoisomerase II catalytic inhibitors | TOPO TARGET APS (DK) | 2003-02-13 | — | — | US | disclosed |
| US-20020161266-A1 | Performing a one-pot organic reaction, which includes carbon monoxide (CO) as reactant and does not use of an external gas source, by contacting a non-catalyzing CO releasing compound such as a metal carbonyl with an energy source | BIOTAGE AB (SE) | 2002-10-31 | — | — | US | disclosed |
| WO-2002078679-A2 | SUCCINIMIDE AND MALEIMIDE DERIVATIVES AND THEIR USE AS TOPOISOMERASE II CATALYTIC INHIBITORS | TOPO TARGET APS (DK) | 2002-10-10 | — | — | WO | disclosed |
| EP-1143955-A3 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| US-20020103176-A1 | Male contraceptive formulation comprising norethisterone | SCHERING AKTIENGESELLSCHAFT | 2002-08-01 | — | — | US | disclosed |
| EP-1218419-A1 | POLYMERIZATION METHOD | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-03 | — | — | EP | disclosed |
| EP-1165601-A2 | PRODRUGS OF THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-02 | — | — | EP | disclosed |
| EP-1143955-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1140203-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001014428-A1 | POLYMERIZATION METHOD | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000061609-A2 | PRODRUGS OF THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-19 | — | — | WO | disclosed |
| US-6120592-A | GAMMA-RADIATION CROSSLINKED FILMS FROM CASEIN AND/OR ITS DERIVATIVES WITH PLASTICIZERS IN CONTROLLED AMOUNTS, FOOD PACKAGING | BRAULT DENIS (CH) | 2000-09-19 | — | — | US | disclosed |
| EP-1019405-A1 | BETA-METHYLCARBAPENEM DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Korea Research Institute of Chemical Technology (KR) | 2000-07-19 | — | — | EP | disclosed |
| WO-2000038666-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000035488-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| EP-0977811-A1 | BIODEGRADABLE FILMS CONTAINING CASEINATE AND THEIR METHOD OF MANUFACTURE BY IRRADIATION | Brault, Denis (CH) | 2000-02-09 | — | — | EP | disclosed |
| WO-2000001802-A2 | PEPTIDE ANTAGONISTS OF THE HUMAN UROKINASE RECEPTOR AND METHOD FOR SELECTING THEM | CANCERFORSKNINGSFONDEN AF 1989 (FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING) (DK) | 2000-01-13 | — | — | WO | disclosed |
| EP-0939757-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | Dupont Pharmaceuticals Company (US) | 1999-09-08 | — | — | EP | disclosed |
| CN-1223271-A | Copolymers of Maleic anhydrdide or acid and fluorinated olefins | DU PONT (US) | 1999-07-21 | — | — | CN | disclosed |
| US-5834499-A | TREATING GASTROINTESTINAL DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| WO-1998049237-A1 | BIODEGRADABLE FILMS CONTAINING CASEINATE AND THEIR METHOD OF MANUFACTURE BY IRRADIATION | BRAULT DENIS (CA) | 1998-11-05 | — | — | WO | disclosed |
| WO-1997023480-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997020844-A1 | β-METHYLCARBAPENEM DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1997-06-12 | — | — | WO | disclosed |
| CN-1150424-A | Compounds for the treatment of retroviral infections | UPJOHN CO (US) | 1997-05-21 | — | — | CN | disclosed |
| CN-1143364-A | 5-HT3 receptor agonist, novel thiazole derivative, and intermediate thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1997-02-19 | — | — | CN | disclosed |
| EP-0749966-A1 | 5-HT 3 RECEPTOR AGONIST, NOVEL THIAZOLE DERIVATIVE, AND INTERMEDIATE THEREFOR | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-12-27 | — | — | EP | disclosed |
| EP-0491872-B1 | POLYHALODIHYDRODIOXINS AND POLYHALODIOXOLES | DU PONT (US) | 1994-08-03 | — | — | EP | disclosed |
| US-5334731-A | Using halogenated dioxoles prepared by the catalytic dechlorination of halogenated dioxolanes | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-08-02 | — | — | US | disclosed |
| EP-0559690-A1 | 8-ENE-19, 11-g(b)-BRIDGED STEROIDS, THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM. | SCHERING AG (DE) | 1993-09-15 | — | — | EP | disclosed |
| EP-0267378-B1 | TROPOLONE DERIVATIVES AS AN ANTI-MYCOPLASMA AGENT | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1992-11-04 | — | — | EP | disclosed |
| EP-0491872-A1 | POLYHALODIHYDRODIOXINS AND POLYHALODIOXOLES. | DU PONT (US) | 1992-07-01 | — | — | EP | disclosed |
| US-5026801-A | Polyhalodihydrodioxins and polyhalodioxoles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-06-25 | — | — | US | disclosed |
| WO-1991004251-A2 | POLYHALODIHYDRODIOXINS AND POLYHALODIOXOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-04-04 | — | — | WO | disclosed |
| WO-1990014354-A1 | STEROIDS WITH A 9α-HYDROXY-19,11β BRIDGE, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1990-11-29 | — | — | WO | disclosed |
| US-4447602-A | Process to prepare 7-substituted cephalosporins or 6-substituted penicillins | MERCK & CO., INC. (US) | 1984-05-08 | — | — | US | disclosed |
| US-4102882-A | Process to prepare novel antibiotic compounds | MERCK & CO., INC. (US) | 1978-07-25 | — | — | US | disclosed |
| US-4041029-A | Acylimine cephalosporins | MERCK & CO., INC. (US) | 1977-08-09 | — | — | US | disclosed |
| US-4041029-A | Acylimine cephalosporins | MERCK & CO., INC. (US) | 1977-08-09 | — | — | US | disclosed |